Abstract
BackgroundBladder cancer (BCA) is the most common urinary tumor, but its pathogenesis is unclear, and the associated treatment strategy has rarely been updated. In recent years, a deeper understanding of tumor epigenetics has been gained, providing new opportunities for cancer detection and treatment.MethodsWe identified prognostic methylation sites based on DNA methylation profiles of BCA in the TCGA database and constructed a specific prognostic subgroup.ResultsBased on the consistent clustering of 402 CpGs, we identified seven subgroups that had a significant association with survival. The difference in DNA methylation levels was related to T stage, N stage, M stage, grade, sex, age, stage and prognosis. Finally, the prediction model was constructed using a Cox regression model and verified using the test dataset; the prognosis was consistent with that of the training set.ConclusionsThe classification based on DNA methylation is closely related to the clinicopathological characteristics of BCA and determines the prognostic value of each epigenetic subtype. Therefore, our findings provide a basis for the development of DNA methylation subtype-specific therapeutic strategies for human bladder cancer.
Highlights
Bladder cancer (BCA) is the most common urinary tumor, but its pathogenesis is unclear, and the associated treatment strategy has rarely been updated
RNA-sequencing data from 433 BCA samples were downloaded from TCGA, and among these, 407 samples were associated with clinical data
Identification prognostic methylation sites associated with overall survival (OS) The prognostic molecular subsets were clustered based on a DNA methylation map of BCA samples in the TCGA database
Summary
Bladder cancer (BCA) is the most common urinary tumor, but its pathogenesis is unclear, and the associated treatment strategy has rarely been updated. Bladder cancer (BCA) is the ninth most common cancer in the world [1], and it is estimated that the number of new BCA cases in the United States will reach 81,400 in 2020, with approximately 17,980 deaths [2]. In patients with BCA, 70% of cases are non-muscular invasive BCA (NMIBC), characterized by a high recurrence rate and low mortality. Cystoscopy is the current gold standard to monitor BCA. This method involves a highly invasive examination and has a sensitivity of 85% for the diagnosis of exophytic tumors [5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
